PROSPECT II, COMBINE (OCT–FFR) and PROSPECT ABSORB: After revascularization of culprit lesions, assessment of coronary plaque size and composition matter!
PROSPECT II, COMBINE (OCT–FFR) and PROSPECT ABSORB trials were presented at TCT Connect 2020. Hector Garcia-Garcia provides a summary of the key messages.
